What does URA represent in the context of drug pricing?

In the context of drug pricing, URA stands for Unit Rebate Amount. This term refers to the specific amount of money that a drug manufacturer agrees to provide as a rebate per unit of a drug that is purchased by covered entities under the 340B Drug Pricing Program.

The importance of the Unit Rebate Amount lies in its role in reducing the cost of medications for eligible healthcare providers who serve vulnerable populations. These rebates are calculated based on the difference between the average manufacturer price and the best price offered to other customers, ensuring that entities participating in the 340B program can access medications at a lower cost.

Understanding URA is crucial because it highlights how manufacturers participate in the 340B program and the financial dynamics involved in drug pricing, which ultimately impacts healthcare access and affordability for patients dependent on these services.